AbbVie (NYSE:ABBV) traded higher in the premarket on Friday after setting its 2025 earnings outlook in line with expectations even as it reported a loss of $22M for Q4 driven by a $3.5B impairment ...
Results that may be inaccessible to you are currently showing.